company background image
BNO

BionomicsASX:BNO Stock Report

Market Cap

AU$146.4m

7D

7.4%

1Y

11.5%

Updated

18 Oct, 2021

Data

Company Financials
BNO fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

BNO Overview

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States.

Price History & Performance

Summary of all time highs, changes and price drops for Bionomics
Historical stock prices
Current Share PriceAU$0.14
52 Week HighAU$0.10
52 Week LowAU$0.48
Beta2.84
1 Month Change-14.71%
3 Month Change-14.71%
1 Year Change11.54%
3 Year Change-12.12%
5 Year Change-61.84%
Change since IPO-78.03%

Recent News & Updates

Shareholder Returns

BNOAU BiotechsAU Market
7D7.4%2.3%0.9%
1Y11.5%1.5%20.2%

Return vs Industry: BNO exceeded the Australian Biotechs industry which returned 1.5% over the past year.

Return vs Market: BNO underperformed the Australian Market which returned 20.2% over the past year.

Price Volatility

Is BNO's price volatile compared to industry and market?
BNO volatility
BNO Beta2.84
Industry Beta1.61
Market Beta1

Stable Share Price: BNO is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: BNO's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
1996n/an/ahttps://www.bionomics.com.au

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company’s lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.

Bionomics Fundamentals Summary

How do Bionomics's earnings and revenue compare to its market cap?
BNO fundamental statistics
Market CapAU$146.39m
Earnings (TTM)-AU$8.70m
Revenue (TTM)AU$928.07k

159.3x

P/S Ratio

-16.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BNO income statement (TTM)
RevenueAU$928.07k
Cost of RevenueAU$5.76m
Gross Profit-AU$4.83m
ExpensesAU$3.86m
Earnings-AU$8.70m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.0086
Gross Margin-520.89%
Net Profit Margin-937.11%
Debt/Equity Ratio0%

How did BNO perform over the long term?

See historical performance and comparison

Valuation

Is Bionomics undervalued compared to its fair value and its price relative to the market?

3.08x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BNO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate BNO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: BNO is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.

PE vs Market: BNO is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BNO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BNO is good value based on its PB Ratio (3.1x) compared to the AU Biotechs industry average (4.9x).


Future Growth

How is Bionomics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bionomics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Bionomics performed over the past 5 years?

19.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BNO is currently unprofitable.

Growing Profit Margin: BNO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BNO is unprofitable, but has reduced losses over the past 5 years at a rate of 19.6% per year.

Accelerating Growth: Unable to compare BNO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BNO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (46.5%).


Return on Equity

High ROE: BNO has a negative Return on Equity (-18.27%), as it is currently unprofitable.


Financial Health

How is Bionomics's financial position?


Financial Position Analysis

Short Term Liabilities: BNO's short term assets (A$30.9M) exceed its short term liabilities (A$2.4M).

Long Term Liabilities: BNO's short term assets (A$30.9M) exceed its long term liabilities (A$4.3M).


Debt to Equity History and Analysis

Debt Level: BNO is debt free.

Reducing Debt: BNO has no debt compared to 5 years ago when its debt to equity ratio was 47.6%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BNO has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: BNO has sufficient cash runway for 2.3 years if free cash flow continues to grow at historical rates of 2.8% each year.


Dividend

What is Bionomics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BNO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BNO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BNO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BNO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BNO's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.4yrs

Average management tenure


CEO

Bionomics has no CEO, or we have no data on them.


Leadership Team

Experienced Management: BNO's management team is considered experienced (2.4 years average tenure).


Board Members

Experienced Board: BNO's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 43.6%.


Top Shareholders

Company Information

Bionomics Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Bionomics Limited
  • Ticker: BNO
  • Exchange: ASX
  • Founded: 1996
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$146.392m
  • Shares outstanding: 1.01b
  • Website: https://www.bionomics.com.au

Location

  • Bionomics Limited
  • 200 Greenhill Road
  • Eastwood
  • South Australia
  • 5063
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/18 15:14
End of Day Share Price2021/10/18 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.